Study identifier:D9612L00096
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Cluster-Randomized Study to Examine National Characteristics and Outcome Measures of GERD patients utilizing the PPI Acid Suppression Symptom (PASS) test for response [EncomPASS].
Gastroesophageal Reflux
Phase 4
No
Esomeprazole
All
2000
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
To characterize the burden of disease in GERD patients of prescription therapy’
Location
Location
Mississauga, ON, Canada
Location
Toronto, ON, Canada
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.